{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T22:47:33Z","timestamp":1772750853435,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,12,19]],"date-time":"2014-12-19T00:00:00Z","timestamp":1418947200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s00592-014-0691-y","type":"journal-article","created":{"date-parts":[[2014,12,19]],"date-time":"2014-12-19T06:53:06Z","timestamp":1418971986000},"page":"539-546","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Cancer and bone fractures in observational follow-up of the RECORD study"],"prefix":"10.1007","volume":"52","author":[{"given":"Nigel P.","family":"Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula S.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip D.","family":"Home","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,12,19]]},"reference":[{"key":"691_CR1","unstructured":"El-Hage J. http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/05\/slides\/2005-4169s2_02_02-fda-elhage.ppt . Accessed Aug 2014"},{"key":"691_CR2","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1007\/s00125-010-1804-y","volume":"53","author":"PD Home","year":"2010","unstructured":"Home PD, Kahn SE, Jones NP, Noronha D, Beck-Nielsen H, Viberti G (2010) Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia 53:1838\u20131845","journal-title":"Diabetologia"},{"key":"691_CR3","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","volume":"355","author":"SE Kahn","year":"2006","unstructured":"Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O\u2019Neill MC, Zinman B, Viberti G, ADOPT Study Group (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427\u20132443","journal-title":"N Engl J Med"},{"key":"691_CR4","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","volume":"373","author":"PD Home","year":"2009","unstructured":"Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJV (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373:2125\u20132135","journal-title":"Lancet"},{"key":"691_CR5","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/00002018-200932030-00002","volume":"32","author":"J Dormandy","year":"2009","unstructured":"Dormandy J, Bhattacharya M, de Bruyn ARV, Investigators P (2009) Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes an overview of data from PROactive. Drug Saf 32:187\u2013202","journal-title":"Drug Saf"},{"key":"691_CR6","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s00125-005-1869-1","volume":"48","author":"PD Home","year":"2005","unstructured":"Home PD, Pocock SJ, Beck-Nielsen H et al (2005) Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 48:1726\u20131735","journal-title":"Diabetologia"},{"key":"691_CR7","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/2036","volume":"4","author":"A-M Lefebvre","year":"1998","unstructured":"Lefebvre A-M, Chen I, Desreumaux P et al (1998) Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL\/6\u00a0J-APCmin\/+\u00a0mice. Nat Med 4:1053\u20131057","journal-title":"Nat Med"},{"key":"691_CR8","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/2042","volume":"4","author":"E Saez","year":"1998","unstructured":"Saez E, Tontonoz P, Nelson MC (1998) Activators of the nuclear receptor PPAR gamma enhance colon polyp formation. Nat Med 4:1058\u20131061","journal-title":"Nat Med"},{"key":"691_CR9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1080\/01926230490261320","volume":"32","author":"MP Pino","year":"2004","unstructured":"Pino MP, Kelley MF, Jayyosi Z (2004) Promotion of colon tumors in c57bl\/6j-apcmin\/+\u00a0mice by thiazolidinedione PPAR\u03b3 agonists and a structurally unrelated PPAR\u03b3 agonist. Toxicol Pathol 32:58\u201363","journal-title":"Toxicol Pathol"},{"key":"691_CR10","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"Dormandy JA, Charbonnel B, Eckland DJ et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro-Vascular Events): a randomised controlled trial. Lancet 366:1279\u20131289","journal-title":"Lancet"},{"key":"691_CR11","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1634\/theoncologist.2012-0302","volume":"18","author":"C Bosetti","year":"2013","unstructured":"Bosetti C, Rosato V, Buniato D, Zambon A, La Vecchia C, Corrao G (2013) Analysis cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis. Oncologist 18:148\u2013156","journal-title":"Oncologist"},{"key":"691_CR12","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3322\/caac.20078","volume":"60","author":"E Giovannucci","year":"2010","unstructured":"Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Yee D et al (2010) Diabetes and cancer: a consensus report. CA Cancer J Clin 60:207\u2013221","journal-title":"CA Cancer J Clin"},{"key":"691_CR13","doi-asserted-by":"crossref","unstructured":"Hatton JL, Yee LD (2008). Clinical use of PPAR\u03b3 ligands in cancer. PPAR Res. doi: 10.1155\/2008\/159415","DOI":"10.1155\/2008\/159415"},{"key":"691_CR14","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/annonc\/mdr534","volume":"23","author":"X He","year":"2012","unstructured":"He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee M-H, Yeung S-CJ (2012) Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2\u00a0+\u00a0breast cancer. Ann Oncol 23:1771\u20131780","journal-title":"Ann Oncol"},{"key":"691_CR15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00592-013-0504-8","volume":"51","author":"M Monami","year":"2014","unstructured":"Monami M, Dicembrini I, Mannucci E (2014) Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials. Acta Diabetol 51:91\u2013101","journal-title":"Acta Diabetol"},{"key":"691_CR16","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4161\/cc.8.2.7584","volume":"8","author":"BE Lyles","year":"2009","unstructured":"Lyles BE, Akinyeke TO, Moss PE, Stewart LV (2009) Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPARgamma-dependent and PPARgamma-independent pathways. Cell Cycle 8:268\u2013277","journal-title":"Cell Cycle"},{"key":"691_CR17","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1200\/JCO.2006.07.2777","volume":"25","author":"R Govindarajan","year":"2007","unstructured":"Govindarajan R, Ratnasinghe L, Simmons DL, Siegel ER, Midathada MV, Kim L, Kim PJ, Owens RJ, Lang NP (2007) Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 25:1476\u20131481","journal-title":"J Clin Oncol"},{"key":"691_CR18","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","volume":"356","author":"SE Nissen","year":"2007","unstructured":"Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular disease. N Engl J Med 356:2457\u20132471","journal-title":"N Engl J Med"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-014-0691-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00592-014-0691-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-014-0691-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T14:00:39Z","timestamp":1559138439000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00592-014-0691-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,19]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["691"],"URL":"https:\/\/doi.org\/10.1007\/s00592-014-0691-y","relation":{},"ISSN":["0940-5429","1432-5233"],"issn-type":[{"value":"0940-5429","type":"print"},{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,19]]}}}